Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

O-GlcNAcylation Induced HMGB1 Signaling as a Molecular Switch for Immune Escape in Esophageal Carcinoma

NCT07702253 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT07702253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07702253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
O-GlcNAcylation Induced HMGB1 Signaling as a Molecular Switch for Immune Escape in Esophageal Carcinoma
Lead sponsor
Chinese University of Hong Kong
Phase
Observational
Overall status
Active, not recruiting
Start date
April 1, 2026
Completion date
March 31, 2037
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal squamous cell carcinoma (escc)